Journal of Liver Cancer最新文献

{"title":"Novel management of expected post-radiotherapy complications in hepatocellular carcinoma patients: a case report.","authors":"Sung Hoon Chang,&nbsp;Tae Suk Kim,&nbsp;Yong Hwan Jeon,&nbsp;Nuri Hyun Jung,&nbsp;Dae Hee Choi","doi":"10.17998/jlc.2022.08.03","DOIUrl":"https://doi.org/10.17998/jlc.2022.08.03","url":null,"abstract":"<p><p>In recent years, radiotherapy (RT) has been used to treat hepatocellular carcinoma (HCC) at each stage. This clinical trend has developed with the increasing improvement of RT techniques, which show clinical results comparable to those of other treatment modalities. Intensity-modulated radiotherapy uses a high radiation dose to improve treatment effectiveness. However, the associated radiation toxicity can damage adjacent organs. Radiation-induced gastric damage with gastric ulcers is a complication of RT. This report presents a novel management strategy for preventing post-RT gastric ulcers. We present the case of a 53-year-old male patient diagnosed with HCC, who experienced gastric ulcer after RT. Before the second round of RT, the patient was administered a gas-foaming agent, which was effective in preventing RT complications.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"183-187"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/83/20/jlc-2022-08-03.PMC10035741.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma.","authors":"Dong-Hyun Kim","doi":"10.17998/jlc.2022.03.28","DOIUrl":"10.17998/jlc.2022.03.28","url":null,"abstract":"<p><p>Interventional oncology (IO) local therapies of hepatocellular carcinoma (HCC) can activate anti-cancer immunity and it is potentially leading to an anti-cancer immunity throughout the body. For the development of an effective HCC treatment regime, great emphasis has been dedicated to different IO local therapy mediated immune modulation and possible combinations with immune checkpoint inhibitor immunotherapy. In this review paper, we summarize the status of combination of IO local therapy and immunotherapy, as well as the prospective role of therapeutic carriers and locally administered immunotherapy in advanced HCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"93-102"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/23/jlc-2022-03-28.PMC10035730.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9754053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma.","authors":"Eun-Ji Choi,&nbsp;Young-Joon Kim","doi":"10.17998/jlc.2022.09.08","DOIUrl":"https://doi.org/10.17998/jlc.2022.09.08","url":null,"abstract":"<p><p>Advances in our knowledge of the molecular characteristics of hepatocellular carcinoma (HCC) have enabled significant progress in the detection and therapeutic prediction of HCC. As a non-invasive alternative to tissue biopsy, liquid biopsy examines circulating cellular components such as exosomes, nucleic acids, and cell-free DNA found in body fluids (e.g., urine, saliva, ascites, and pleural effusions) and provides information about tumor characteristics. Technical advances in liquid biopsy have led to the increasing adoption of diagnostic and monitoring applications for HCC. This review summarizes the various analytes, ongoing clinical trials, and case studies of United States Food and Drug Administrationapproved in vitro diagnostic applications for liquid biopsy, and provides insight into its implementation in managing HCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"103-114"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/ed/jlc-2022-09-08.PMC10035729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9736741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study.","authors":"Jeong Yun Jang,&nbsp;Jinhong Jung,&nbsp;Danbi Lee,&nbsp;Ju Hyun Shim,&nbsp;Kang Mo Kim,&nbsp;Young-Suk Lim,&nbsp;Han Chu Lee,&nbsp;Jin-Hong Park,&nbsp;Sang Min Yoon","doi":"10.17998/jlc.2022.08.18","DOIUrl":"https://doi.org/10.17998/jlc.2022.08.18","url":null,"abstract":"<p><strong>Background/aim: </strong>We aimed to investigate the efficacy and safety of stereotactic body radiation therapy (SBRT) in elderly patients with small hepatocellular carcinomas (HCC).</p><p><strong>Methods: </strong>Eighty-three patients (89 lesions) with HCC who underwent SBRT between January 2012 and December 2018 were reviewed in this retrospective observational study. The key inclusion criteria were as follows: 1) age ≥75 years, 2) contraindications for hepatic resection or percutaneous ablative therapies, 3) no macroscopic vascular invasion, and 4) no extrahepatic metastasis.</p><p><strong>Results: </strong>The patients were 75-90 years of age, and 49 (59.0%) of them were male. Most patients (94.0%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Seventy-four patients (89.2%) had Child-Pugh class A hepatic function before SBRT. The median tumor size was 1.6 cm (range, 0.7-3.5). The overall median follow-up period was 34.8 months (range, 7.3-99.3). The 5-year local tumor control rate was 90.1%. The 3-year and 5-year overall survival rate was 57.1% and 40.7%, respectively. Acute toxicity grade ≥3 was observed in three patients (3.6%) with elevated serum hepatic enzymes; however, no patient experienced a worsening of the Child-Pugh score to ≥2 after SBRT. None of the patients developed late toxicity (grade ≥3).</p><p><strong>Conclusions: </strong>SBRT is a safe treatment option with a high local control rate in elderly patients with small HCC who are not eligible for other curative treatments.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"136-145"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/1c/jlc-2022-08-18.PMC10035735.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The dual role of transforming growth factor-beta signatures in human B viral multistep hepatocarcinogenesis: early and late responsive genes.","authors":"Jeong Eun Yoo,&nbsp;Ji Hae Nahm,&nbsp;Young-Joo Kim,&nbsp;Youngsic Jeon,&nbsp;Young Nyun Park","doi":"10.17998/jlc.2022.04.20","DOIUrl":"https://doi.org/10.17998/jlc.2022.04.20","url":null,"abstract":"<p><strong>Background/aim: </strong>Transforming growth factor-beta (TGF-β) has a dichotomous role, functioning as a tumor suppressor and tumor promoter. TGF-β signatures, explored in mouse hepatocytes, have been reported to predict the clinical outcomes of hepatocellular carcinoma (HCC) patients; HCCs exhibiting early TGF-β signatures showed a better prognosis than those with late TGF-β signatures. The expression status of early and late TGF-β signatures remains unclear in defined lesions of human B-viral multistep hepatocarcinogenesis.</p><p><strong>Methods: </strong>The expression of TGF-β signatures, early and late responsive signatures of TGF-β were investigated and analyzed for their correlation in cirrhosis, low-grade dysplastic nodules (DNs), high-grade DNs, early HCCs and progressed HCCs (pHCCs) by real-time PCR and immunohistochemistry.</p><p><strong>Results: </strong>The expression levels of TGF-β signaling genes (<i>TGFB1</i>, <i>TGFBR1</i>, <i>TGFBR2</i> and <i>SMAD4</i>) gradually increased with the progression of hepatocarcinogenesis, peaking in pHCCs. The expression of early responsive genes of TGF-β (<i>GADD45B</i>, <i>FBP1</i>, <i>CYP1A2</i> and <i>CYP3A4</i>) gradually decreased, and that of the late TGF-β signatures (<i>TWIST</i> and <i>SNAI1</i>) significantly increased according to the progression of multistep hepatocarcinogenesis. Furthermore, mRNA levels of <i>TWIST</i> and <i>SNAI1</i> were well correlated with those of stemness markers, with upregulation of TGF-β signaling, whereas <i>FBP1</i> expression was inversely correlated with that of stemness markers.</p><p><strong>Conclusions: </strong>The enrichment of the late responsive signatures of TGF-β with induction of stemness is considered to be involved in the progression of the late stage of multistep hepatocarcinogenesis, whereas the early responsive signatures of TGF-β are suggested to have tumor-suppressive roles in precancerous lesions of the early stage of multistep hepatocarcinogenesis.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"115-124"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/94/jlc-2022-04-20.PMC10035736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment.","authors":"Young-Hwan Ahn,&nbsp;Heirim Lee,&nbsp;Ji Eun Han,&nbsp;Hyo Jung Cho,&nbsp;Jae Youn Cheong,&nbsp;Bumhee Park,&nbsp;Soon Sun Kim","doi":"10.17998/jlc.2022.05.24","DOIUrl":"https://doi.org/10.17998/jlc.2022.05.24","url":null,"abstract":"<p><strong>Background/aim: </strong>There has been a long-standing debate about the association of directacting antiviral (DAA) therapy and hepatocellular carcinoma (HCC) recurrence. This study aimed to investigate the association between DAA therapy and HCC recurrence after curative therapy.</p><p><strong>Methods: </strong>We retrospectively enrolled 1,021 patients with HCV-related (hepatitis C virus) HCC who underwent radiofrequency ablation (RFA), liver resection, or both as the first treatment modality from January 2007 to December 2016 and without a history of HCV therapy before HCC treatment from a nationwide database. The effect of HCV treatment on HCC recurrence and all-cause mortality was also investigated.</p><p><strong>Results: </strong>Among the 1,021 patients, 77 (7.5%) were treated with DAA, 14 (1.4%) were treated with interferon-based therapy, and 930 (91.1%) did not receive HCV therapy. DAA therapy was an independent prognostic factor for lower HCC recurrence rate (hazard ratio [HR], 0.04; 95% confidence interval [CI], 0.006-0.289; <i>P</i>=0.001 for landmarks at 6 months after HCC treatment and HR, 0.05; 95% CI, 0.007-0.354; <i>P</i>=0.003 for landmarks at 1 year). Furthermore, DAA therapy was associated with lower all-cause mortality (HR, 0.049; 95% CI, 0.007-0.349; <i>P</i>=0.003 for landmarks at 6 months and HR, 0.063; 95% CI, 0.009-0.451; <i>P</i>=0.006 for landmarks at 1 year).</p><p><strong>Conclusions: </strong>DAA therapy after curative HCC treatment can decrease HCC recurrence and all-cause mortality compared to interferon-based therapy or no antiviral therapy. Therefore, clinicians should consider administering DAA therapy after curative HCC treatment in patients with HCV-related HCC.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"125-135"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/d4/jlc-2022-05-24.PMC10035739.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9754055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocellular carcinoma diagnosed in a patient who had Fontan operation 30 years ago: a case report.","authors":"Moon Haeng Hur,&nbsp;Haeryoung Kim,&nbsp;Jeong-Hoon Lee","doi":"10.17998/jlc.2022.08.17","DOIUrl":"https://doi.org/10.17998/jlc.2022.08.17","url":null,"abstract":"<p><p>The Fontan operation is performed in patients with a single ventricle. As the systemic venous return is directly connected to the pulmonary circulation during this procedure, chronic hepatic congestion is induced, leading to Fontan-associated liver disease (FALD) including liver cirrhosis and hepatocellular carcinoma (HCC). In this report, we present a case of HCC diagnosed in a patient who underwent the Fontan operation 30 years ago. The patient underwent regular surveillance for FALD, which revealed a 4 cm-sized hepatic mass with elevated serum alpha-fetoprotein. After surgical treatment, there was no evidence of HCC recurrence during 3 years of follow-up. As the risk of HCC and Fontan-associated liver cirrhosis increases with the duration elapsed since the operation, regular surveillance should be emphasized. Serial follow-up of serum alpha-fetoprotein levels and abdominal imaging are necessary to achieve early and accurate diagnosis of HCC in post-Fontan patients.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"188-193"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/cb/jlc-2022-08-17.PMC10035737.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9739877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?","authors":"Hye Won Lee","doi":"10.17998/jlc.2022.09.20","DOIUrl":"https://doi.org/10.17998/jlc.2022.09.20","url":null,"abstract":"Whether direct-acting antiviral (DAA) treatment can prevent hepatocellular carcinoma (HCC) recurrence is a subject of debate. In a prior study, Ahn et al. 1 investigated cases of hepatitis C virus (HCV)-related HCC in patients who received curative treatment using a nationwide database; spe-cifically, the authors investigated whether DAA therapy following curative HCC treatment decreased the likelihood of HCC recurrence compared to interferon (IFN)-based thera-pies or no treatment. 1 Notably, several studies have shown an unexpectedly high rate of early HCC recurrence in patients with HCV-related HCC following DAA treatment. 2 Addi-tionally, in a landmark analysis, DAA treatment significantly reduced all-cause mortality compared to no treatment at 6 and 12 months after the first HCC treatment. Several questions remain unanswered in the DAA era: the first concerns the optimal time to start DAA","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"91-92"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/54/be/jlc-2022-09-20.PMC10035738.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9806891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis.","authors":"Young Chang, Soung Won Jeong, Jae Young Jang, Hyuksoo Eun, Young-Sun Lee, Do Seon Song, Su Jong Yu, Sae Hwan Lee, Won Kim, Hyun Woong Lee, Sang Gyune Kim, Seongho Ryu, Suyeon Park","doi":"10.17998/jlc.2022.09.19","DOIUrl":"10.17998/jlc.2022.09.19","url":null,"abstract":"<p><strong>Background/aim: </strong>New biomarkers are urgently needed to aid in the diagnosis of early stage hepatocellular carcinoma (HCC). We performed a meta-analysis on the diagnostic utility of circulating tumor DNA (ctDNA) levels in patients with hepatitis B virus-induced HCC.</p><p><strong>Methods: </strong>We retrieved relevant articles from PubMed, Embase, and the Cochrane Library up to February 8, 2022. Two subgroups were defined; one subset of studies analyzed the ctDNA methylation status, and the other subset combined tumor markers and ctDNA assays. Pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC) were analyzed.</p><p><strong>Results: </strong>Nine articles including 2,161 participants were included. The overall SEN and SPE were 0.705 (95% confidence interval [CI], 0.629-0.771) and 0.833 (95% CI, 0.769-0.882), respectively. The DOR, PLR, and NLR were 11.759 (95% CI, 7.982-17.322), 4.285 (95% CI, 3.098-5.925), and 0.336 (0.301-0.366), respectively. The ctDNA assay subset exhibited an AUC of 0.835. The AUC of the combined tumor marker and ctDNA assay was 0.848, with an SEN of 0.761 (95% CI, 0.659-0.839) and an SPE of 0.828 (95% CI, 0.692-0.911).</p><p><strong>Conclusions: </strong>Circulating tumor DNA has promising diagnostic potential for HCC. It can serve as an auxiliary tool for HCC screening and detection, especially when combined with tumor markers.</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"167-177"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/a4/jlc-2022-09-19.PMC10035733.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9734389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yoon et al. Hepatocellular Carcinoma in Korea: an Analysis of the 2015 Korean Nationwide Cancer Registry.","authors":"Jeong-Hoon Lee","doi":"10.17998/jlc.21.1.58.e1","DOIUrl":"https://doi.org/10.17998/jlc.21.1.58.e1","url":null,"abstract":"<p><p>[This retracts the article on p. 58 in vol. 21.].</p>","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"22 2","pages":"207"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/64/45/jlc-21-1-58-e1.PMC10035732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9806889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}